Charles River Laboratories (CRL) to Acquire Cognate BioServices for $875 Million

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. IBM
4. SPCX
5. ACN
6. NVDA
7. PRIM
8. META
9. SPY
10. DPZ

Go back to Charles River Laboratories (CRL) to Acquire Cognate BioServices for $875 Million

Charles River Labs (CRL) PT Raised to $301 at Credit Suisse

February 17, 2021 4:13 PM EST

Credit Suisse analyst Erin Wilson Wright raised the price target on Charles River Labs (NYSE: CRL) to $301.00 (from $259.00) while maintaining a Neutral rating.

The analyst comments "CRLs 4Q EPS ($2.39) handily exceeded our $2.04 on stronger revenues and profitability. Below the line factors also added $0.15. It... More

Charles River Laboratories (CRL) Tops Q4 EPS by 29c, Revenues Beat; Offers FY21 EPS Guidance Above Consensus

February 17, 2021 7:11 AM EST

Charles River Laboratories (NYSE: CRL) reported Q4 EPS of $2.39, $0.29 better than the analyst estimate of $2.10. Revenue for the quarter came in at $791 million versus the consensus estimate of $756.86 million.

Fourth-Quarter Revenue of $791.0 Million and Full-Year Revenue of $2.92 Billion Fourth-Quarter GAAP Earnings per Share of $2.81 and Non-GAAP Earnings per Share of $2.39 Full-Year GAAP Earnings per Share of $7.20 and Non-GAAP Earnings per Share of $8.13 Announces Definitive Agreement to Acquire Cognate BioServices, A Premier, Cell and Gene Therapy CDMO

GUIDANCE:

Charles River Laboratories sees FY2021 EPS of... More